Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Perspective Therapeutics, Inc.

Market Cap 339M 293M 270M 252M 473M 32.2B 480M 3.18B 1.24B 15.67B 1.27B 1.24B 54.26B P/E Ratio 2026 *
-2.69x
P/E Ratio 2027 * -2.6x
Enterprise Value 152M 131M 121M 113M 212M 14.41B 215M 1.42B 555M 7.01B 569M 557M 24.28B EV / Sales 2026 *
369x
EV / Sales 2027 * 55.2x
Free-Float
89.19%
Yield 2026 *
-
Yield 2027 * -
1 day-0.17%
1 week-2.15%
Current month-24.75%
1 month-21.35%
3 months-41.98%
6 months+11.05%
Current year+7.82%
1 week 2.85
Extreme 2.85
3.13
1 month 2.85
Extreme 2.85
4.34
Current year 2.25
Extreme 2.25
6.16
1 year 1.96
Extreme 1.955
6.16
3 years 1.6
Extreme 1.6
19.05
5 years 1.6
Extreme 1.6
19.05
10 years 1.6
Extreme 1.6
28.1
Manager TitleAgeSince
Chief Executive Officer 54 2023-02-04
Director of Finance/CFO 59 2025-09-03
Chief Tech/Sci/R&D Officer - 2022-03-31
Director TitleAgeSince
Director/Board Member 54 2023-02-04
Chairman 63 2023-02-02
Director/Board Member 60 2023-02-04
Date Insider Type Main position Quantity % Market Cap.
Mar. 01Free

Director

50,000 0.0439%
Mar. 01Free

Chairman

50,000 0.0439%
Mar. 01Free

Director

50,000 0.0439%
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%-2.15%-7.92%-45.60% 339M
-0.35%+0.97%-15.96%-12.73% 42.96B
+2.87%+3.03%+273.98%+507.45% 31.73B
+0.20%-1.51%+13.54%-14.73% 30.22B
+1.67%-1.91%-4.19%+24.27% 28.94B
+4.09%-1.98%+11.99%+17.37% 23.87B
-1.66%+3.18%+54.18%+114.98% 13.57B
-0.40%-1.48%+7.48%+7.12% 12.96B
+2.05%+5.16% - - 13.39B
-0.74%-1.81%+105.32%+75.68% 12.2B
Average +0.79%-1.50%+48.71%+74.87% 21.02B
Weighted average by Cap. +1.06%-1.09%+54.35%+95.46%

Financials

2026 *2027 *
Net sales 411K 355K 327K 306K 573K 39.03M 582K 3.86M 1.5M 19M 1.54M 1.51M 65.77M 478K 413K 381K 356K 668K 45.48M 678K 4.5M 1.75M 22.14M 1.8M 1.76M 76.64M
Net income -121M -105M -96.31M -90.15M -169M -11.5B -172M -1.14B -443M -5.6B -454M -444M -19.38B -142M -122M -113M -106M -198M -13.48B -201M -1.33B -519M -6.56B -532M -521M -22.71B
Net Debt -187M -162M -149M -139M -261M -17.79B -265M -1.76B -686M -8.66B -702M -687M -29.98B -312M -270M -249M -233M -436M -29.68B -443M -2.93B -1.14B -14.45B -1.17B -1.15B -50.03B
Logo Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Employees
165
Date Price Change Volume
26-06-12 2.950 $ -0.67% 1,025,063
26-06-11 2.970 $ +0.68% 1,052,849
26-06-10 2.950 $ -1.67% 1,141,452
26-06-09 3.000 $ +2.39% 1,491,131
26-06-08 2.930 $ -3.30% 1,263,134
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.970USD
Average target price
12.93USD
Spread / Average Target
+335.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CATX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!